SEC For	m 4																	
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB	APPRO	VAL
Section obligat	this box if no lo n 16. Form 4 or ions may contin tion 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNI Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									_	HIP	Estim	Numbe ated av	erage burde	3235-0287 n 0.5		
1. Name and Address of Reporting Person <sup>*</sup> Mahoney Robert Patrick					Comera Life Sciences Holdings, Inc. [ CMRA ]								RA (Che	i. Relationship of Reporting Person(s) to Iss Check all applicable) Director 10% Ov X Officer (give title Other (s below) below)			wner	
(Last) C/O COI	(F MERA LIF	(Middle) HOLDINGS, INC.			Date 0 /27/2		Trans	saction (Mor	nth/D	ay/Year)		Chief Scientific Officer						
12 GILL STREET, SUITE 4650 (Street) WOBURN MA			01801			. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing Line) X Form filed by One Report Form filed by More than Person								rting Perso	n			
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication   Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
1. Title of Security (Instr. 3) 2. Transi						ction 2A. Deemed					ties Acquir	ed (A) or	5. Amoun				7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Date (Month/				Day/Year)   i		Execution Date if any (Month/Day/Yea		ar) Code (Ir 8)		Amount	(A) o (D)	r Price	Beneficiall Owned Fol Reported		llowing (I) (Ins			
			Table II -						uired, Di s, options					Owned		1	1	1
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	C	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Numbo derivativ Securitie Beneficia Owned Followin Reported	e s ally g	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				C	ode	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	Transaction(s) (Instr. 4)		
Stock Option (Right to Purchase)	\$0.376	09/27/2023			A		300,000		(1)	0	9/27/2033	Common Stock	300,000	\$0	300,0	00	D	

Explanation of Responses:

1. 25% of the shares underlying the stock option vest on September 27, 2024, with the remaining shares vesting on a monthly basis on the 27th day of each month thereafter, in each case, subject to continuous service to the issuer, such that the option shall be fully vested on September 27, 2027.

## <u>/s/ Ryan M. Rourke Reed,</u> <u>Attorney-in-Fact</u>

09/28/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.